Catalyst Wire Dossier Catalyst Wire Dossier
CLINICAL_TRIALS trial_result · 2019-01-29

Clinical Trial Update: Role of High Mobility Group Box 1 as a Prognostic Biomarker in Patients Undergoing Valvular Heart Surgery

View source ↗

Summary

Completed clinical trial evaluating high mobility group box 1 (HMGB1) as a prognostic biomarker in patients undergoing valvular heart surgery.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

Snippet

Sponsor: Yonsei University | Conditions: Valvular Heart Disease | Status: COMPLETED